Polyrizon Completes Enrollment of 120 Patients in U.S. NASARIX Study
Polyrizon says enrollment is complete for all 120 patients in its U.S. clinical study of the NASARIX allergy blocker.
Polyrizon says enrollment is complete for all 120 patients in its U.S. clinical study of the NASARIX allergy blocker.